The 200,000-square-foot project increases Agilent’s capacity to meet demand for the company’s synthetic oligonucleotides, which help treat cancer, cardiovascular disease, and other rare diseases. The project will be built in accordance with Process Safety Management standards.
“It is great to be part of project that will improve the care available for people that are facing a wide range of health care challenges,” said Scott Bustos, Vice President and General Manager of Turner Construction Company. “I thank Agilent for their trust in the technical expertise of our people and for their investment in the Frederick, Colorado, community that will have such a broad and positive impact on society.”
The project is scheduled for completion in 2026.
Turner is a North America-based, international construction services company and is a builder in diverse market segments. With a staff of 10,000 employees, the company completes $12 billion of construction on 1,500 projects each year.